The deal will boost Boston Scientific’s electrophysiology and structural heart product portfolios.
Medtech businesses show tremendous potential for profitability and growth, triggering a sparked interest in investment.
Although transactions were down, they exceeded more than $450 million last month.
Although the medtech industry is expected to enjoy steady growth, device companies are still challenged to attract the skilled labor that manufacturing requires.
Analysts expect 2020 to be a busy year for M&A activity.
Eighty medtech transactions in Europe came in at a value of approximately $627.5 million.
The deal is expected to close in the second half of 2020, but one analyst expects the transaction will raise antitrust issues in the United States.
The total value of deals for 2019 exceeds $30 billion.
Medical device companies will be driven to evolve their business models to a more patient/consumer-centric approach.
Overall activity in deals jumped 11% in North America.